First animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
List view / Grid view
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.